Needham & Company Starts Clearside Biomedical (CLSD) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- CAE agrees to sell Flightscape unit to SITA for $500 million
Cowen Starts Clearside Biomedical (CLSD) at Outperform
June 27, 2016 6:46 AM EDTCowen initiated coverage on Clearside Biomedical (NASDAQ: CLSD) with an Outperform rating.
For an analyst ratings summary and ratings history on Clearside Biomedical click here. For more ratings news on Clearside Biomedical click here.
Shares of Clearside Biomedical closed at $6.80 yesterday.
... MoreWedbush Starts Clearside Biomedical (CLSD) at Outperform, $28 PT
June 27, 2016 6:20 AM EDTWedbush initiates coverage on Clearside Biomedical (NASDAQ: CLSD) with a Outperform rating and a price target of $28.00.
Analyst Liana Moussatos commented, "We believe an investment in CLSD supports a dramatic improvement in injectable drug delivery for multiple eye diseases."
She added, "Clearside is a... More



